PDCD1 and hepatocellular carcinoma: Moreover, clinical trial investigations have demonstrated that nivolumab, a PD-1 monoclonal antibody, when combined with radiotherapy for HCC, exhibits promising safety and efficacy (de la Torre-Aláez et al., 2022).